Zakhra Magomedova

Dr. Zakhra Magomedova

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
GMGeorge Makiev
George Makiev
ISIgor Samoylenko
Igor Samoylenko
VNValeria V. Nazarova
Valeria V. Nazarova
ZMZakhra Magomedova
Zakhra Magomedova
ATAlexey Tryakin
Alexey Tryakin
TGTigran G. Gevorkyan
Tigran G. Gevorkyan
Background: The persistently low 5-year survival rate for pancreatic cancer (PC) underscores the critical need for early detection. However, population-wide screening remains impractical. Artificial Intelligence (AI) models using electronic health record (EHR) data offer a promising avenue for pre-symptomatic risk stratification. Objective: To systematically review and meta-analyze the performance of AI models for PC prediction based exclusively on structured EHR data. Methods: We systematically searched PubMed, MedRxiv, BioRxiv, and Google Scholar (2010–2025). Inclusion criteria encompassed studies using EHR-derived data (excluding imaging/genomics), applying AI for PC prediction, reporting AUC, and including a non-cancer cohort. Two reviewers independently extracted data. Random-effects meta-analysis was performed for AUC, sensitivity (Se), and specificity (Sp) using R software version 4.5.1. Heterogeneity was assessed using I2 statistics and publication bias was evaluated. Results: Of 946 screened records, 19 studies met the inclusion criteria. The pooled AUC across all models was 0.785 (95% CI: 0.759–0.810), indicating good overall discriminatory ability. Neural Network (NN) models demonstrated a statistically significantly higher pooled AUC (0.826) compared to Logistic Regression (LogReg, 0.799), Random Forests (RF, 0.762), and XGBoost (XGB, 0.779) (all p < 0.001). In analyses with sufficient data, models like Light Gradient Boosting (LGB) showed superior Se and Sp (99% and 98.7%, respectively) compared to NNs and LogReg, though based on limited studies. Meta-analysis of Se and Sp revealed extreme heterogeneity (I2 ≥ 99.9%), and the positive predictive values (PPVs) reported across studies were consistently low (often < 1%), reflecting the challenge of screening a low-prevalence disease. Conclusions: AI models using EHR data show significant promise for early PC detection, with NNs achieving the highest pooled AUC. However, high heterogeneity and typically low PPV highlight the need for standardized methodologies and a targeted risk-stratification approach rather than general population screening. Future prospective validation and integration into clinical decision-support systems are essential.

6 September 2024 in Voprosy onkologii
Verified
Journal Article
Open access
ZMZakhra Magomedova
Zakhra Magomedova
ВНВалерия Витальевна Назарова
Валерия Витальевна Назарова
KOKristina Orlova
Kristina Orlova
ВУВладимир Михайлович Унгурян
Владимир Михайлович Унгурян
ЛДЛев Вадимович Демидов
Лев Вадимович Демидов
Увеальная меланома редкая внутриглазная опухоль, несмотря на все успехи в лечении первичной опухоли, более чем у 50 % пациентов развивается метастатическая форма заболевания. Увеальная меланома отличается по своим молекулярно-биологическим особенностям (другие драйверные мутации, меньшая мутационная нагрузка) от меланомы кожи, и если для меланомы кожи достигнуты определённые успехи в лечении (таргетная терапия, иммунотерапия), то для увеальной меланомы продолжаются поиски новых мишеней и подходов. В статье приведены исследования, отражающие эффективность и безопасность основных системных и локальных методов лечения, а также набирающих в последнее время популярность комбинированных подходов в лечении метастатической увеальной меланомы.

4 April 2024 in Effective Pharmacotherapy
Verified
Journal Article
Closed access
ZMZakhra Magomedova
Zakhra Magomedova
NUN.I. Pirogov Russian National Research Medical University
N.I. Pirogov Russian National Research Medical University
VNV.V. Nazarova
V.V. Nazarova
KOK.V. Orlova
K.V. Orlova
ISI.V. Samoylenko
I.V. Samoylenko
M2Medsi Clinical Hospital No. 2
Medsi Clinical Hospital No. 2
Количество случаев меланомы кожи ежегодно неуклонно растет, что приводит к увеличению случаев меланомы, ассоциированной с беременностью. На сегодняшний день нет

22 February 2026 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
IOI. Yu. Oganesyan
I. Yu. Oganesyan
VNV. V. Nazarova
V. V. Nazarova
OVOlga Voskresenskaya
Olga Voskresenskaya
ZMZakhra Magomedova
Zakhra Magomedova
DPD. E. Prokhorov
D. E. Prokhorov
SNSh. R. Nabiev
Sh. R. Nabiev
Immunotherapy using immune checkpoint inhibitors (ICIs) has demonstrated efficacy in treating a wide range of oncological diseases, but the use of this group of drugs is associated with the risk of developing serious immune-related adverse events (irAEs). Although relatively rare, neurological complications associated with ICI use are often life-threatening. The most common of these include myositis, myasthenia (with or with-out myositis), peripheral neuropathies, including Guillain–Barre syndrome, autoimmune encephalitis, myelitis, and demyelinating syndromes. This article presents five clinical observations of the development of neurological complications against the background of the use of anti-PD-1 inhibitors (pembrolizumab, nivolumab) as monotherapy or in combination with an anti-CTLA-4 inhibitor (ipilimumab). The cases presented were diagnosed with transverse myelitis, peripheral neuropathies meeting the diagnostic criteria for chronic inflammatory demyelinating polyneuropathy, and myositis, including in combination with myasthenia gravis. To relieve these conditions, glucocorticoids were used in the form of pulse therapy followed by oral administration, high-volume plasmapheresis, and cytostatic drugs. The treatment provided resulted in marked clinical improvement. The observations presented emphasise the importance of early diagnosis and effective treatment of irAEs as well as a multidisciplinary approach to the management of such patients. To date, the problems of selecting the optimal management strategy for irAEs and assessing the safety of subsequent ICIs use remain relevant and require further prospective studies. In addition to demonstrating the importance of a multidisciplinary approach, the purpose of presenting these observations is to raise awareness among neurologists about neurological immune-related adverse events caused by ICI therapy.    The relevance of this task  is determined by the fact that the widespread introduction of ICI into clinical practice for the treatment of various malignant neoplasms will inevitably lead to an increase in such cases in neurological practice, which predetermines the need for neurologists to be prepared to diagnose and manage such patients.

22 April 2026 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
ASA. Yu. Syryseva
A. Yu. Syryseva
ISI. G. Shabanov
I. G. Shabanov
ESE. A. Shatokhina
E. A. Shatokhina
NDN. V. Danilova
N. V. Danilova
KOKristina Orlova
Kristina Orlova
VNValeria V. Nazarova
Valeria V. Nazarova
The article presents a review of immune-related cutaneous adverse events associated with checkpoint inhibitors. Pathogenetic mechanisms of immune-related complications associated with T cell hyperactivation and disruption of peripheral tolerance are considered. Clinical and pathomorphological characteristics of the most common skin reactions are described: maculopapular rash, itch, lichenoid and psoriasiform rashes, bullous pemphigoid, as well as rare and life-threatening syndromes such as drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), Stevens–Johnson syndrome, toxic epidermal necrolysis. Special attention is paid to the analysis of psoriasiform rashes and exacerbation of psoriasis vulgaris which are associated with significant diagnostic difficulties and require differential approach to treatment. To demonstrate the importance of early involvement of a dermatologist for diagnosis verification (including skin biopsy) and prescription of pathogenetically justified steroid-sparing therapy, clinical cases are presented. Multidisciplinary approach and personalized management of patients with immune-related cutaneous adverse events allow to control skin toxicity, minimize the necessity of checkpoint inhibitor cancellation, and preserve efficacy of antitumor treatment.

15 April 2025 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
ISIgor Samoylenko
Igor Samoylenko
VNV. V. Nazarova
V. V. Nazarova
ZMZakhra Magomedova
Zakhra Magomedova
PKP. V. Kononets
P. V. Kononets
IBI. M. Borovkov
I. M. Borovkov
TGT. G. Gevorkyan
T. G. Gevorkyan
Background. Lung cancer remains one of the leading causes of mortality, with early detection significantly improving prognosis. Modern approaches require new solutions for more effective screening patient selection.Aim. To conduct a systematic review of studies applying artificial intelligence (AI) for analyzing socio-demographic data and routine laboratory tests to optimize patient selection for screening and pathology classification.Materials and methods. A literature search (2014–2024) was conducted in databases including PubMed, ResearchGate, and Scopus. Included studies analyzed the use of AI for lung cancer risk prediction based on sociodemographic data and medical records.Results. The analysis identified 5 studies of AI-based models that were applied to select candidates for lung cancer screening. Age, smoking, chronic lung disease, and BMI were the most frequently used factors in the AI models. The models demonstrated high sensitivity (up to 92,7 %) and area under the receiver operating characteristic (up to 0.90). The results confirmed that AI can improve the accuracy of patient selection for screening compared to traditional methods.Conclusion. AI application for lung cancer risk prediction shows substantial potential, especially with combined use of socio-demographic and medical record data. Further studies are needed to improve models and evaluate their clinical impact.